一名接受维莫非尼BRAF抑制剂治疗的IV期黑色素瘤患者发生双侧全葡萄膜炎。
Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.
作者信息
Agemy Steven A, Mehta Ankur N, Pachydaki Sophia I, Tewari Asheesh
机构信息
Department of Ophthalmology, Kresge Eye Institute/Wayne State University School of Medicine, Detroit, Michigan - USA.
出版信息
Eur J Ophthalmol. 2014 Jul-Aug;24(4):629-32. doi: 10.5301/ejo.5000423. Epub 2014 Jan 22.
PURPOSE
To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.
METHODS
Case report.
RESULTS
A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication.
CONCLUSIONS
Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.
目的
描述一例由BRAF原癌基因抑制剂维莫非尼引起的复发性双侧全葡萄膜炎病例。
方法
病例报告。
结果
一名25岁女性在开始使用BRAF酶抑制剂维莫非尼治疗IV期皮肤黑色素瘤后出现双侧全葡萄膜炎和黄斑水肿。患者通过球后注射曲安奈德并停药得到成功治疗。
结论
全葡萄膜炎是维莫非尼的一种潜在不良反应。如有必要停药，与肿瘤学专家进行良好沟通很有必要。
Zotero 插件